PwC's Roel van den Akker says pharma M&A ran beyond expectations in the first half of 2026, with dealmaking potentially on pace to hit $300 billion in H2.
Roel van den Akker
Advertisement
Roel van den Akker is the Deals partner at PwC.
Articles by Roel van den Akker
Roel van den Akker examines how the industry might evolve its trade, distribution, and payer strategies to scale GLP-1s for mass demand.
Roel van den Akker evaluates how blockbuster GLP-1s may shift broader commercialization trends.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Supply Chain Signal: Domestic Manufacturing and the German Pricing Standoff
2
Cencora's Brent Wilhelm on the Inventory Paradox Behind Drug Shortages
3
Mid-Year Check-In: Will Pharma M&A Keep Pace?
4
The New Era of Pharma Distribution: Balancing Precision and Scale
5